Sami A. Chadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sami A. Chadi has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Dhruvin H. Hirpara
Department of Surgery, University of Toronto, Toronto, Canada
6 shared publicationsFayez A. Quereshy
Department of Surgery, University of Toronto, Toronto, Ontario, Canada
6 shared publications- Keegan Guidolin
Department of Surgery University of Toronto Toronto Ontario Canada
5 shared publications Fayez Quereshy
Department of Surgery University of Toronto Toronto Ontario Canada
4 shared publicationsKeegan Guidolin
Department of Surgery, University of Toronto, Toronto, Ontario, Canada
4 shared publications- Ronald Burkes
Department of Medicine, Mount Sinai Hospital, Sinai Health, Toronto, ON M5G 1X5, Canada
4 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (5) , 274
A Consensus Approach to the Incorporation of Total Neoadjuvant Therapy in a Treatment Algorithm for Stage I–III Resectable Rectal Cancer
Advances in surgical techniques, radiographic imaging capabilities, radiotherapy, and chemotherapy have led to improved outcomes for patients with rectal adenocarcinoma. Treatment strategies have correspondingly evolved, as seen with total neoadjuvant therapy (TNT) and organ preservation approaches. TNT is a treatment strategy for primary, non-metastatic, resectable mismatch repair proficient rectal cancer where the intent is to administer all appropriate adjuvant therapy in the preoperative phase, including both systemic therapy and chemoradiotherapy/radiotherapy. In this setting, TNT is increasingly administered for the purposes of maximizing tumour response to facilitate resection, improving treatment compliance, thus increasing the likelihood of a complete response to allow for organ preservation and for the possibility of improving survival. While several recent randomized controlled trials have described the role of TNT in the contemporary treatment of rectal cancer, there is significant heterogeneity in sequencing of treatments, dosing, allowance for non-operative management, and the potential for over-treatment. Our objective here was to incorporate current evidence to develop a consensus-based institutional treatment algorithm to be used in the ambulatory and multidisciplinary team setting for the treatment of stage I–III rectal cancer.
- 8 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (5) , 274
Open AccessA Consensus Approach to the Incorporation of Total Neoadjuvant Therapy in a Treatment Algorithm for Stage I–III Resectable Rectal Cancer
Advances in surgical techniques, radiographic imaging capabilities, radiotherapy, and chemotherapy have led to improved outcomes for patients with rectal adenocarcinoma. Treatment strategies have correspondingly evolved, as seen with total neoadjuvant therapy (TNT) and organ preservation approaches. TNT is a treatment strategy for primary, non-metastatic, resectable mismatch repair proficient rectal cancer where the intent is to administer all appropriate adjuvant therapy in the preoperative phase, including both systemic therapy and chemoradiotherapy/radiotherapy. In this setting, TNT is increasingly administered for the purposes of maximizing tumour response to facilitate resection, improving treatment compliance, thus increasing the likelihood of a complete response to allow for organ preservation and for the possibility of improving survival. While several recent randomized controlled trials have described the role of TNT in the contemporary treatment of rectal cancer, there is significant heterogeneity in sequencing of treatments, dosing, allowance for non-operative management, and the potential for over-treatment. Our objective here was to incorporate current evidence to develop a consensus-based institutional treatment algorithm to be used in the ambulatory and multidisciplinary team setting for the treatment of stage I–III rectal cancer.
- Open Access
Synthesis of existing literature on the colorectal surgery patients’ challenges during hospital-to-home transitions: a scoping review protocol
Introduction Despite advances in innovation to improve patients’ transition experiences, it is unclear—in the context of colorectal surgery—what elements of patient education and care could provide the greatest benefit to patient experiences and clinical outcomes. Thus, this scoping review protocol aims to outline a plan to synthesise the existing literature from countries with publicly funded health systems (ie, Australia, Canada, France, Germany, the Netherlands, New Zealand, Sweden, the United Kingdom and the USA) on the challenges experienced by colorectal surgery patients’ when transitioning home from the hospital. Methods and analysis This is a protocol for a scoping review to identify literature relating to adult patient challenges experienced when transitioning from hospital to home following colorectal surgery. We will search the following databases for studies published between 2012 and present: Ovid MEDLINE; Ovid Embase; Cochrane Database of Systematic Reviews (Ovid) and Cochrane Central Register of Controlled Trials (Ovid). Title, abstract and full-text review will be conducted independently by at least two reviewers. Data will be extracted, collated, summarised and reported numerically (eg, frequency counts) and presented using descriptive summaries. In addition, data related to the challenges reported by colorectal surgery patients during their transition home from the hospital will be descriptively analysed using deductive content analysis. The extracted challenges will be categorised according to the International Classification of Functioning, Disability and Health and the surgical transition trajectory (eg, predischarge, during discharge and postdischarge) to identify when in the patient journey is the best point to implement improved practices and achieve patient-centred care. Ethics and dissemination This protocol does not require ethics approval as data have not been collected or analysed. The findings will highlight insights into patient care transitions following colorectal surgery, which will be disseminated via publications and presentations.
Open AccessSynthesis of existing literature on the colorectal surgery patients’ challenges during hospital-to-home transitions: a scoping review protocol
Introduction Despite advances in innovation to improve patients’ transition experiences, it is unclear—in the context of colorectal surgery—what elements of patient education and care could provide the greatest benefit to patient experiences and clinical outcomes. Thus, this scoping review protocol aims to outline a plan to synthesise the existing literature from countries with publicly funded health systems (ie, Australia, Canada, France, Germany, the Netherlands, New Zealand, Sweden, the United Kingdom and the USA) on the challenges experienced by colorectal surgery patients’ when transitioning home from the hospital. Methods and analysis This is a protocol for a scoping review to identify literature relating to adult patient challenges experienced when transitioning from hospital to home following colorectal surgery. We will search the following databases for studies published between 2012 and present: Ovid MEDLINE; Ovid Embase; Cochrane Database of Systematic Reviews (Ovid) and Cochrane Central Register of Controlled Trials (Ovid). Title, abstract and full-text review will be conducted independently by at least two reviewers. Data will be extracted, collated, summarised and reported numerically (eg, frequency counts) and presented using descriptive summaries. In addition, data related to the challenges reported by colorectal surgery patients during their transition home from the hospital will be descriptively analysed using deductive content analysis. The extracted challenges will be categorised according to the International Classification of Functioning, Disability and Health and the surgical transition trajectory (eg, predischarge, during discharge and postdischarge) to identify when in the patient journey is the best point to implement improved practices and achieve patient-centred care. Ethics and dissemination This protocol does not require ethics approval as data have not been collected or analysed. The findings will highlight insights into patient care transitions following colorectal surgery, which will be disseminated via publications and presentations.
- 5 May 2024
- Published by Wiley in Colorectal Disease
- Vol. 26 (7) , 1467-1468
Low anterior resection with natural orifice specimen extraction performed with the HUGO robotic assisted surgery system—a video vignette
- 5 May 2024
- Published by Wiley in Colorectal Disease
- Vol. 26 (7) , 1467-1468
Low anterior resection with natural orifice specimen extraction performed with the HUGO robotic assisted surgery system—a video vignette
- Open Access
- 9 November 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (11) , 9836-9848
Iron Surveillance and Management in Gastro-Intestinal Oncology Patients: A National Physician Survey
Purpose: Iron deficiency (ID) is a complication of gastrointestinal (GI) cancers that may manifest as iron deficiency anemia (IDA). Serum ferritin monitoring and oral iron supplementation have the limitations of being falsely elevated and poorly absorbed, respectively. This study aims to assess the discordance in surveillance, treatment practices, and awareness of ID/IDA in GI cancer patients by Canadian physicians treating these patients. Methods: From February 2020 to September 2021, a 22-question electronic survey was sent to medical oncologists (MOs), surgical oncologists (SOs), and gastroenterologists (GEs). The survey collected information about four domains: physician demographics, surveillance practices, treatment practices, and awareness of ID/IDA in GI cancer patients and ASCO/ASH guidelines. Results: A total of 108 (34 MOs, 19 SOs, and 55 GEs) of the 872 (12.4%) invited physicians completed the survey. Of these, 26.5% of MOs, 36.8% of SOs, and 70.9% of GEs measured baseline iron parameters, with few continuing surveillance throughout treatment. Ferritin was widely measured by MOs (88.9%), SOs (100%), and GEs (91.4%). Iron was supplemented if ID/IDA was identified pre-treatment by 66.7% of MOs, 85.7% of SOs, and 94.2% of GEs. Parenteral iron was prescribed by SOs (100%), while oral iron was prescribed by MOs (83.3%) and GEs (87.9%). Only 18.6% of physicians were aware of the ASCO/ASH guidelines regarding erythropoiesis-stimulating agents with parenteral iron for treating chemotherapy-induced anemia. Conclusion: Results illustrate variations in practice patterns for IDA management across the different physician specialties. Moreover, there appeared to be gaps in the knowledge and care surrounding evidence-based IDA management principles which may contribute to poor clinical outcomes.
- 9 November 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (11) , 9836-9848
Open AccessIron Surveillance and Management in Gastro-Intestinal Oncology Patients: A National Physician Survey
Purpose: Iron deficiency (ID) is a complication of gastrointestinal (GI) cancers that may manifest as iron deficiency anemia (IDA). Serum ferritin monitoring and oral iron supplementation have the limitations of being falsely elevated and poorly absorbed, respectively. This study aims to assess the discordance in surveillance, treatment practices, and awareness of ID/IDA in GI cancer patients by Canadian physicians treating these patients. Methods: From February 2020 to September 2021, a 22-question electronic survey was sent to medical oncologists (MOs), surgical oncologists (SOs), and gastroenterologists (GEs). The survey collected information about four domains: physician demographics, surveillance practices, treatment practices, and awareness of ID/IDA in GI cancer patients and ASCO/ASH guidelines. Results: A total of 108 (34 MOs, 19 SOs, and 55 GEs) of the 872 (12.4%) invited physicians completed the survey. Of these, 26.5% of MOs, 36.8% of SOs, and 70.9% of GEs measured baseline iron parameters, with few continuing surveillance throughout treatment. Ferritin was widely measured by MOs (88.9%), SOs (100%), and GEs (91.4%). Iron was supplemented if ID/IDA was identified pre-treatment by 66.7% of MOs, 85.7% of SOs, and 94.2% of GEs. Parenteral iron was prescribed by SOs (100%), while oral iron was prescribed by MOs (83.3%) and GEs (87.9%). Only 18.6% of physicians were aware of the ASCO/ASH guidelines regarding erythropoiesis-stimulating agents with parenteral iron for treating chemotherapy-induced anemia. Conclusion: Results illustrate variations in practice patterns for IDA management across the different physician specialties. Moreover, there appeared to be gaps in the knowledge and care surrounding evidence-based IDA management principles which may contribute to poor clinical outcomes.
- Open Access
- 26 October 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (11) , ofad523
Clostridium difficile Enteritis With NAP7/078 Toxigenic Strain
To the Editor—We recently treated a patient with severe Clostridium difficile enteritis, and we believe that this rare syndrome would be of interest to Open Forum Infectious Diseases readers. We present our case in the context of prior literature and identify salient gaps with the role of toxigenic strains and treatment guidelines for this diagnosis with significant mortality.
- 26 October 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (11) , ofad523
Open AccessClostridium difficile Enteritis With NAP7/078 Toxigenic Strain
To the Editor—We recently treated a patient with severe Clostridium difficile enteritis, and we believe that this rare syndrome would be of interest to Open Forum Infectious Diseases readers. We present our case in the context of prior literature and identify salient gaps with the role of toxigenic strains and treatment guidelines for this diagnosis with significant mortality.
- 2 March 2023
- Published by Springer Nature in Surgical Endoscopy
- Vol. 37 (4) , 2528-2537
The SAGES MASTERS program presents: the top 10 seminal articles for laparoscopic left and sigmoid colectomy pathway for uncomplicated disease
Background As one of the 8 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Masters Program clinical pathways, the Colorectal Pathway aims to deliver educational content for the general surgeon organized along 3 levels of performance (competency, proficiency and mastery) each represented by an anchoring procedure. In this article, the SAGES Colorectal Task Force presents focused summaries of the top 10 seminal articles selected for laparoscopic left/sigmoid colectomy for uncomplicated disease. Methods Using a systematic literature search of Web of Science, the most cited articles on laparoscopic left and sigmoid colectomy were identified, reviewed, and ranked by members of the SAGES Colorectal Task Force. Additional articles not identified in the literature search were included if deemed impactful by expert consensus. The top 10 ranked articles were then summarized, including their findings, strengths and limitations with emphasis on relevance and impact in the field. Results The top 10 articles selected focus on variations in minimally invasive surgical techniques, video demonstrations, stratified approaches for benign and malignant disease as well as assessments of the learning curve. Conclusions The selected top 10 seminal articles for laparoscopic left and sigmoid colectomy in uncomplicated disease are considered by the SAGES colorectal task force to be fundamental to the knowledge base of minimally invasive surgeons as they progress to mastery in these procedures.
- 2 March 2023
- Published by Springer Nature in Surgical Endoscopy
- Vol. 37 (4) , 2528-2537
The SAGES MASTERS program presents: the top 10 seminal articles for laparoscopic left and sigmoid colectomy pathway for uncomplicated disease
Background As one of the 8 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Masters Program clinical pathways, the Colorectal Pathway aims to deliver educational content for the general surgeon organized along 3 levels of performance (competency, proficiency and mastery) each represented by an anchoring procedure. In this article, the SAGES Colorectal Task Force presents focused summaries of the top 10 seminal articles selected for laparoscopic left/sigmoid colectomy for uncomplicated disease. Methods Using a systematic literature search of Web of Science, the most cited articles on laparoscopic left and sigmoid colectomy were identified, reviewed, and ranked by members of the SAGES Colorectal Task Force. Additional articles not identified in the literature search were included if deemed impactful by expert consensus. The top 10 ranked articles were then summarized, including their findings, strengths and limitations with emphasis on relevance and impact in the field. Results The top 10 articles selected focus on variations in minimally invasive surgical techniques, video demonstrations, stratified approaches for benign and malignant disease as well as assessments of the learning curve. Conclusions The selected top 10 seminal articles for laparoscopic left and sigmoid colectomy in uncomplicated disease are considered by the SAGES colorectal task force to be fundamental to the knowledge base of minimally invasive surgeons as they progress to mastery in these procedures.
- Open Access
- 25 January 2023
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 158 (4) , 425-426
Evaluation of Financial Relationships Between US Colorectal Surgery Fellowship Program Directors and Industry
In 2010, the Physician Payments Sunshine Act was enacted in the US to promote transparency of physician-industry relationships as they may impact clinical practice. In 2013, the act mandated public reporting of payments by industry to licensed physicians.1 Program directors (PDs) of surgical fellowships have a unique opportunity to shape their programs and impact their trainees’ practice. This study sought to quantify financial relationships between colorectal surgery fellowship PDs and industry.
- 25 January 2023
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 158 (4) , 425-426
Open AccessEvaluation of Financial Relationships Between US Colorectal Surgery Fellowship Program Directors and Industry
In 2010, the Physician Payments Sunshine Act was enacted in the US to promote transparency of physician-industry relationships as they may impact clinical practice. In 2013, the act mandated public reporting of payments by industry to licensed physicians.1 Program directors (PDs) of surgical fellowships have a unique opportunity to shape their programs and impact their trainees’ practice. This study sought to quantify financial relationships between colorectal surgery fellowship PDs and industry.
- 8 October 2022
- Published by Wiley in Colorectal Disease
- Vol. 25 (3) , 509-510
A stepwise approach to laparoscopic splenic flexure mobilization – A Video Vignette
- 8 October 2022
- Published by Wiley in Colorectal Disease
- Vol. 25 (3) , 509-510
A stepwise approach to laparoscopic splenic flexure mobilization – A Video Vignette
- 2 July 2022
- Published by Elsevier in Annals of Oncology
- Vol. 33, S261
P-42 Iron surveillance and management in gastrointestinal oncology patients: A national survey of physician practice
- 2 July 2022
- Published by Elsevier in Annals of Oncology
- Vol. 33, S261
P-42 Iron surveillance and management in gastrointestinal oncology patients: A national survey of physician practice
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , e13644
Iron surveillance and management in gastrointestinal oncology patients: A national survey of physician practice.
E13644 Background: In 2018, there were an estimated 4.8 million new cases of gastrointestinal (GI) cancers worldwide and 3.4 million related deaths. Iron deficiency (ID) is a frequent complication of GI malignancy that eventually manifests as iron deficiency anemia (IDA). Early recognition and treatment of ID/IDA in GI oncology patients is an important aspect of care. Traditional serum ferritin monitoring and oral iron supplementation hold limited diagnostic and therapeutic value in this population as it may be falsely elevated and confounded by poor absorption and blood loss, respectively. Therefore, we conducted a survey of Canadian physicians to assess disparities in IDA surveillance and management practices in GI cancer patients. Methods: From February 2020 to September 2021, a 20-question electronic survey was sent to Canadian medical oncologists (MO), surgical oncologists (SO), and gastroenterologists (GE). The survey collected information on four domains: demographics, screening practices, treatment practices, and knowledge of the latest guidelines of ID/IDA. Analysis was conducted using descriptive statistics. Results: A total of 108 (55 GE, 19 SO, and 34 MO) of the 872 (12.4%) invited physicians completed the survey. A greater proportion of GE (70.9% compared to 36.8% of SO, and 26.5% of MO) measured baseline iron parameters. Of these, a slight trend of iron parameters were being measured mainly at initial consult (61.5% of GE, 85.7% of SO, and 44.4% of MO), with little continuing surveillance throughout treatment course. Most physicians who measured iron parameters relied on ferritin mainly (82.1% of GE, 100% of SO), while MO were evenly distributed in their evaluation of ferritin (88.9%), serum iron (100%), total iron binding capacity (100%) and iron saturation (88.9%). The majority supplemented iron if ID/IDA was identified prior to systemic/surgical oncologic treatment (94.2% of GE, 85.7% SO, and 66.7% of MO). Of these, parenteral iron was the preferred modality for SO (85.7%), while oral iron was preferred among GE (82.8%) and MO (55.6%). The majority of physicians (81.3%) were not aware of the ASH/ASCO guidelines regarding the use of erythropoiesis stimulating agents in conjunction with parenteral iron supplementation for treatment anemia in this setting (92% of GE, 66.7% of SO, and 80.9% of MO). Conclusions: Results from this Canadian survey suggests a disparity in practice pattern for IDA management between different specialties caring for GI oncology patients. Moreover, there appears to be a gap in knowledge and thus a gap in care surrounding evidence-based IDA management principles which may be contributing to poor clinical outcomes. Focused knowledge translation and exchange efforts are required to improve treatment of ID/IDA in patients with GI cancer nationally.
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , e13644
Iron surveillance and management in gastrointestinal oncology patients: A national survey of physician practice.
E13644 Background: In 2018, there were an estimated 4.8 million new cases of gastrointestinal (GI) cancers worldwide and 3.4 million related deaths. Iron deficiency (ID) is a frequent complication of GI malignancy that eventually manifests as iron deficiency anemia (IDA). Early recognition and treatment of ID/IDA in GI oncology patients is an important aspect of care. Traditional serum ferritin monitoring and oral iron supplementation hold limited diagnostic and therapeutic value in this population as it may be falsely elevated and confounded by poor absorption and blood loss, respectively. Therefore, we conducted a survey of Canadian physicians to assess disparities in IDA surveillance and management practices in GI cancer patients. Methods: From February 2020 to September 2021, a 20-question electronic survey was sent to Canadian medical oncologists (MO), surgical oncologists (SO), and gastroenterologists (GE). The survey collected information on four domains: demographics, screening practices, treatment practices, and knowledge of the latest guidelines of ID/IDA. Analysis was conducted using descriptive statistics. Results: A total of 108 (55 GE, 19 SO, and 34 MO) of the 872 (12.4%) invited physicians completed the survey. A greater proportion of GE (70.9% compared to 36.8% of SO, and 26.5% of MO) measured baseline iron parameters. Of these, a slight trend of iron parameters were being measured mainly at initial consult (61.5% of GE, 85.7% of SO, and 44.4% of MO), with little continuing surveillance throughout treatment course. Most physicians who measured iron parameters relied on ferritin mainly (82.1% of GE, 100% of SO), while MO were evenly distributed in their evaluation of ferritin (88.9%), serum iron (100%), total iron binding capacity (100%) and iron saturation (88.9%). The majority supplemented iron if ID/IDA was identified prior to systemic/surgical oncologic treatment (94.2% of GE, 85.7% SO, and 66.7% of MO). Of these, parenteral iron was the preferred modality for SO (85.7%), while oral iron was preferred among GE (82.8%) and MO (55.6%). The majority of physicians (81.3%) were not aware of the ASH/ASCO guidelines regarding the use of erythropoiesis stimulating agents in conjunction with parenteral iron supplementation for treatment anemia in this setting (92% of GE, 66.7% of SO, and 80.9% of MO). Conclusions: Results from this Canadian survey suggests a disparity in practice pattern for IDA management between different specialties caring for GI oncology patients. Moreover, there appears to be a gap in knowledge and thus a gap in care surrounding evidence-based IDA management principles which may be contributing to poor clinical outcomes. Focused knowledge translation and exchange efforts are required to improve treatment of ID/IDA in patients with GI cancer nationally.